Merck KGaA v Generic Health Pty Ltd

Link copied
Case Copied 22 min read

TRADE MARKS ACT 1995



DECISION OF A DELEGATE OF THE REGISTRAR OF TRADE MARKS WITH REASONS

Re:Application 1041864(5),(35) SASTIN to register a trade mark by Generic Health Pty Ltd and opposition thereto by Merck KGaA.

Delegate: Iain Thompson
Representation: Applicant.  Written submissions by Justin Vaastra of Arnold Bloch Leibler
Opponent:  Trevor Stevens of Davies Collison Cave
Decision:
  1. s52 proceedings – ss 44 and 60 – evidence does not establish reputation of trade mark ZACTIN on which the opponent relies; trade marks SASTIN and ZACTIN not deceptively similar, discussion of impact of public policy issues in comparison of trade marks, opposition not established.

Background

  1. Generic Health Pty Ltd (‘the applicant’) of Elsternwick, Victoria, has filed application to register a trade mark, current details of which are:

    App No:  1041864

    Filing Date:  14 February 2005

    Goods:Class: 5  Pharmaceutical preparations and substances

    Class: 35Distribution of goods; import services not being transport services

    Trade Mark:  SASTIN

  2. Following advertisement of acceptance of the trade mark for possible registration on 16 June 2005, Merck KGaA, of Darmstadt, Germany, (‘the opponent’) served and filed Notice of Opposition to registration of the trade mark on 12 September 2005.  The opponent has served and filed evidence in support of its opposition in accordance with the Trade Marks Act 1995 (‘the Act’) and regulations thereto.  The applicant has not served and filed evidence in answer.

  3. Prior to the hearing before me as a delegate of the Registrar of Trade Marks in Sydney on 16 October 2006, Justin Vaastra of Arnold Bloch Leibler, Solicitors, filed written submissions for the applicant; Trevor Stevens of Davies Collison Cave, Patent & Trade Mark Attorneys, represented the applicant at the hearing.

  4. The submissions of the parties focussed on sections 44 and 60 of the Act.

    Evidence

  5. The evidence comprises a statutory declaration by Mark Hurley, Business Development Manager of Alphapharm Pty Ltd, a wholly owned subsidiary of the opponent, with exhibits 1 to 4.  There are also four trade declarations served and filed in support of the opposition by dispensing pharmacists Messrs Stephen Thompson, Terry Herfort, Ian Gillard, and William Morgan.  I will state now that these trade declarations which are in the form of a questionnaire cannot be regarded as being of high probative weight: the four declarations are in common form with spaces left for the answers to questions, the most relevant one of which is:

    Based on my experience within the pharmaceutical industry it is my opinion that the word SASTIN is sufficiently similar to trade mark ZACTIN to cause confusion if applied to the same or similar goods.  This opinion is based on the following considerations – that is:

    ___________________________________________________________________________________________________________________________________________________________________________________________________

  6. The lines underneath are left for a handwritten ‘answer’.  However, the printed portion of the proforma declarations do not allow for any other conclusion but that the trade marks are confusingly similar.  Additionally, the declarants do not state that they personally would be confused by the similarity of the trade marks – they state that they are of…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Merck KGaA v Generic Health Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2007] ATMO 1
Decision Date

CaseChat Overview and Summary

Merck KGaA (the applicant) sought to register the trade mark SASTIN, while Alphapharm Pty Ltd (the opponent) opposed this application. The dispute concerned whether the proposed trade mark SASTIN was deceptively similar to the opponent's registered trade mark ZACTIN, which was used for pharmaceutical preparations for the treatment of major depressant disorders and obsessive compulsive disorders. The matter was heard by Ian Thompson, Hearing Officer, at Trade Marks Hearings.

The primary legal issues before the Hearing Officer were whether the applicant's trade mark SASTIN infringed sections 44 and 60 of the relevant Act. Section 44 typically deals with the registration of trade marks that are identical or deceptively similar to earlier trade marks, while section 60 addresses the use of trade marks that are likely to deceive or cause confusion. The opponent argued that the similarity between SASTIN and ZACTIN would lead to confusion among patients, pharmacists, and doctors, particularly given the serious nature of the conditions treated by the respective pharmaceuticals and the potential for dangerous contraindications.

The Hearing Officer found that the evidence presented by the opponent, particularly the statutory declarations from dispensing pharmacists, lacked sufficient probative weight. These declarations were in a common form, with pre-printed statements suggesting similarity, and did not clearly articulate personal confusion on the part of the declarants. Instead, they expressed an opinion about potential confusion among others. Consequently, the Hearing Officer determined that the opponent had not established its grounds of opposition under sections 44 and 60 of the Act.

As the applicant was successful in the proceedings, the Hearing Officer ordered that the trade mark application number 1041864 proceed to registration one month from the date of the decision, unless an appeal was filed. The opponent was ordered to pay the applicant's costs.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

The submissions of the parties focussed on sections 44 and 60 of the Act. Evidence The evidence comprises a statutory declaration by Mark Hurley, Business Development Manager of Alphapharm Pty Ltd, a wholly owned subsidiary of the opponent, with exhibits 1 to 4. There are also four trade declarations served and filed in support of the opposition by dispensing pharmacists Messrs Stephen Thompson, Terry Herfort, Ian Gillard, and William Morgan. I will state now that these trade declarations which are in the form of a questionnaire cannot be regarded as being of high probative weight: the four declarations are in common form with spaces left for the answers to questions, the most relevant one of which is:Based on my experience within the pharmaceutical industry it is my opinion that the word SASTIN is sufficiently similar to trade mark ZACTIN to cause confusion if applied to the same or similar goods. This opinion is based on the following considerations – that is:___________________________________________________________________________________________________________________________________________________________________________________________________ The lines underneath are left for a handwritten ‘answer’. However, the printed portion of the proforma declarations do not allow for any other conclusion but that the trade marks are confusingly similar. Additionally, the declarants do not state that they personally would be confused by the similarity of the trade marks – they state that they are of the opinion that the trade marks are sufficiently similar to cause confusion amongst other people who include patients, pharmacists, and doctors. Such trade declarations can be afforded more weight if they are couched in such a way that it is obvious that the declarant freely states that he or she personally would be, or is, or has been, confused by the similarity of the trade marks. It is additionally unclear as to whether these dispensing pharmacists were the only ones approached in a survey or whether they were the only ones who could be found who agreed with whoever it was who approached them. Mr Hurley attests to the registration of the opponent’s trade mark ZACTIN under 659362 in Australia. This registration is in Class 5 of the International (Nice) Classification of Goods and Services for, “Pharmaceutical preparations for the treatment of major depressant disorders.” The opponent’s trade mark is, Mr Hurley says, used in Australia in relation to a drug to treat major depressant disorders and obsessive compulsive disorders. This pharmaceutical sold under the opponent’s trade mark ZACTIN is available only on prescription by a doctor and is a serotonin reuptake inhibitor. There is a wide range of pharmaceuticals that are contra-indicated once the opponent’s pharmaceutical sold under the trade mark ZACTIN has been prescribed for a patient. The latter part of Mr Hurley’s evidence relates to the dangers that might arise through the confusion of pharmaceuticals which have similar looking or sounding trade marks. There are several articles or reports in this part of the evidence and I will discuss this issue in general, and this evidence, as is necessary in the course of my decision.

Decision

Reasons for decision

Section 55 of the Act provides:Decision55. Unless the proceedings are discontinued or dismissed, the Registrar must, at the end, decide:(a) to refuse to register the trade mark; or(b) to register the trade mark (with or without conditions or limitations) in respect of the goods and/or services then specified in the application;having regard to the extent (if any) to which any ground on which the application was opposed has been established.Note: For limitations see section 6. The opponent has not established its grounds under which the opposition was argued at the hearing under sections 44 and 60 for the reasons stated above. For the sake of completeness, I note that those other grounds listed on the Notice of Opposition have not been established. Trade mark application number 1041864 may therefore proceed to registration one month from the date of this decision. If the Registrar has been served with notice of appeal before that time, I direct that the disposition of the application be in accordance with the Court’s direction or order.Costs As the applicant has been successful in these proceedings, I order costs against the opponent at the scale set out in the regulations.Ian ThompsonHearing OfficerTrade Marks Hearings15 January 2007

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.